1,955K shares changed hands on Wednesday. Volume was up 226.43% over the stocks average daily volume.
Short traders are feeling a little more bullish lately at least if you consider the motion in short interest. The company experienced a fall in short interest between September 29, 2017 and October 13, 2017 of -12.70%. Short shares fell 799,313 over that period. The short-interest ratio decreased to 7.0 and the percentage of shorted shares was 0.12% on October 13.
The following firms have recently changed their position in ACOR. As of quarter end Hudson Executive Capital LP had bought a total of 120,410 shares growing its holdings by 15.6%. The value of the investment in ACOR increased from $15,230,000 to $21,131,000 increasing 38.7% quarter over quarter. As of the end of the quarter Clearbridge Investments, LLC had acquired 338 shares growing its position 0.0%. The value of the total investment in Acorda Therapeutics went from $18,694,000 to $22,450,000 a change of 20.1% quarter to quarter.
As of the end of the quarter Partner Fund Management, L.p. had acquired a total of 1,464,132 shares growing its stake by 56.6%. The value in dollars increased from $50,987,000 to $95,837,000 a change of $44,850,000 since the last quarter. Scopia Capital Management Lp expanded its position by buying 1,250,822 shares an increase of 17.3% from 06/30/2017 to 09/30/2017. Scopia Capital Management Lp now controls 8,474,728 shares worth $200,427,000. The total value of its holdings increased 40.8%.
On November 9 analysts at Oppenheimer Holdings issued a report on ACOR with an initial rating of “Market Perform”. CIBC released research on ACOR giving it an initial rating of “Market Perform”.
On November 8, 2017 HC Wainwright updated coverage of ACOR with a rating of “Buy”. Equity analyst Jefferies Group LLC raised the price target on November 1 changing the price objective from $22.00 to $25.00 with a “Hold” recommendation.
Equity analyst J P Morgan Chase & Co released a research note on ACOR and giving a rating of “Hold” and establishing a price target of $24.00. On October 31 Cantor Fitzgerald maintained a stock rating of “Hold” with a current price target of $18.00.
The company is trading up by 0.44% since yesterday’s close of 17. Acorda Therapeutics currently has a P/E ratio of N/A and market capitalization is 798.21M. In the last earnings report the EPS was $-1.21 with 46.75M shares presently outstanding.
Acorda Therapeutics, Inc., launched on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS..